PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID.
Morna J DorseyArye RubinsteinHeather LehmanTracy FausnightJoseph M WileyElie J HaddadPublished in: Journal of clinical immunology (2023)
Elapegademase was safe, well tolerated, achieved stable trough plasma ADA activity with weekly dosing, was effective in maintaining metabolic detoxification, and was associated with maintenance or improvements in lymphocyte counts compared with pegademase therapy in patients with ADA-SCID.
Keyphrases